Immunovia - Public Comps and Valuation Multiples

Immunovia Overview

About Immunovia

Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Founded

2007

HQ

Employees

Website

immunovia.com

Sectors

Medical Imaging & Diagnostics
HealthTech

Financials

LTM Revenue $0.2M

LTM EBITDA -$10.1M

EV

$10.8M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Immunovia Financials

As of September 2025, Immunovia reported last 12-month revenue of $0.2M and EBITDA of -$10.1M.

In the same period, Immunovia generated $0.1M in LTM gross profit and -$14.8M in net income.

See Immunovia valuation multiples based on analyst estimates

Immunovia P&L

In the most recent fiscal year, Immunovia reported revenue of $0.1M and EBITDA of -$6.4M.

Immunovia expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Immunovia valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$0.2M	XXX	$0.1M	XXX	XXX	XXX
Gross Profit	$0.1M	XXX	$0.1M	XXX	XXX	XXX
Gross Margin	56%	XXX	100%	XXX	XXX	XXX
EBITDA	-$10.1M	XXX	-$6.4M	XXX	XXX	XXX
EBITDA Margin	-5333%	XXX	-6581%	XXX	XXX	XXX
EBIT	-$10.5M	XXX	-$11.5M	XXX	XXX	XXX
EBIT Margin	-5522%	XXX	-11766%	XXX	XXX	XXX
Net Profit	-$14.8M	XXX	-$8.1M	XXX	XXX	XXX
Net Margin	-7811%	XXX	-8221%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Immunovia including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $0.2M. EBITDA for the last twelve months was -$10.1M. In the most recent fiscal year, Immunovia achieved $0.1M in revenue and -$6.4M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$0.2M	Analyst estimates available to subscribers	$0.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$0.1M	Analyst estimates available to subscribers	$0.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	55.6% gross margin	Analyst estimates available to subscribers	100.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$10.1M	Analyst estimates available to subscribers	-$6.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-5333.3% EBITDA margin	Analyst estimates available to subscribers	-6580.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$10.5M	Analyst estimates available to subscribers	-$11.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-5522.2% EBIT margin	Analyst estimates available to subscribers	-11765.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$14.8M	Analyst estimates available to subscribers	-$8.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-7811.1% net profit margin	Analyst estimates available to subscribers	-8221.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Immunovia

This financial data table provides comprehensive performance metrics for Immunovia, a company based in Sweden. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Immunovia generated $0.2M in revenue over the last twelve months.
The company achieved -$10.1M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $0.1M.
Net income over the last twelve months reached -$14.8M.

Fiscal Year Performance

In the most recent fiscal year, Immunovia reported $0.1M in total revenue.
Fiscal year EBITDA was -$6.4M.
The company maintained a gross profit margin of 100.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was -6580.6%.
Net profit margin reached -8221.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Immunovia. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Immunovia Stock Performance

Immunovia has current market cap of SEK 131M (or $13.8M), and EV of SEK 103M (or $10.8M).

Market Cap Evolution

Immunovia Stock Data

As of October 17, 2025, Immunovia's stock price is SEK 0 (or $0).

See Immunovia trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$10.8M	$13.8M	XXX	XXX	XXX	XXX	$-0.05

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Immunovia Valuation Multiples

Immunovia's trades at 110.3x EV/Revenue multiple, and -1.7x EV/EBITDA.

See valuation multiples for Immunovia and 15K+ public comps

Immunovia Financial Valuation Multiples

As of October 17, 2025, Immunovia has market cap of $13.8M and EV of $10.8M.

Equity research analysts estimate Immunovia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Immunovia has a P/E ratio of -0.9x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$13.8M	XXX	$13.8M	XXX	XXX	XXX
EV (current)	$10.8M	XXX	$10.8M	XXX	XXX	XXX
EV/Revenue	57.0x	XXX	110.3x	XXX	XXX	XXX
EV/EBITDA	-1.1x	XXX	-1.7x	XXX	XXX	XXX
EV/EBIT	-1.0x	XXX	-0.9x	XXX	XXX	XXX
EV/Gross Profit	102.7x	XXX	n/a	XXX	XXX	XXX
P/E	-0.9x	XXX	-1.7x	XXX	XXX	XXX
EV/FCF	-1.0x	XXX	-1.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Immunovia Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Immunovia Margins & Growth Rates

Immunovia's last 12 month revenue growth is 322%

Immunovia's revenue per employee in the last FY averaged $11K, while opex per employee averaged $1.3M for the same period.

Immunovia's rule of 40 is -10253% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Immunovia's rule of X is -4528% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Immunovia and other 15K+ public comps

Immunovia Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	322%	XXX	211%	XXX	XXX	XXX
EBITDA Margin	-5333%	XXX	-6581%	XXX	XXX	XXX
EBITDA Growth	3%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-10253%	XXX	-6258%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-4528%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$11K	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	11866%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial